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Abstract 
 
 Historically, only cells of the adaptive immune system have been considered capable of 
retaining memory for infectious challenges. Recently however, cells of the innate immune system 
have been shown to be capable of displaying long-term functional memory following a single 
immunostimulatory challenge, leading to enhanced production of proinflammatory molecules upon 
other subsequent, and temporally distant, immunostimulatory challenges. This effect has been 
termed “trained innate immunity”, and is underwritten by stable epigenetic changes in immune and 
metabolic pathways. Importantly, the long-term training of innate immune cells can ocurr as a result 
of infectious as well as and non-infectious challenges, including stress. Given the role that both 
stress and an activated immune system play in neuropathology, innate immune training has 
important implications for our understanding and treatment of neuropsychiatric disorders. This 
review fosuses on the evidence for trained innate immunity and highlights some insights into its 
relevance for psychiatric diseases.  
 
 
 
 
 
 
 
 
 
Introduction 
 
  (Neuro)inflammation is increasingly recognised as a critical factor in the pathogenesis of 
numerous psychiatric illnesses. Indeed, research on immune dysregulation and psychiatric disorders 
has gained significant attention in recent years as data gathered from numerous experimental 
models have converged to provide support for the role of inflammatory mechanisms in the etiology 
of depression, schizophrenia and related psychotic disorders 1. Over the last five years the number 
of publications on immunity and depression alone were almost doubled 2 and similarly, in the past 
seven years data supporting an immune-mediated cause in schizophrenia also escalated 3. This 
advocates that research is now entering a new era of immunopsychiatric investigations that will 
profoundly change the understanding of brain disorders, in which immune impairments will be now 
acknowledged as potential underlying mechanisms of altered behavioural manifestations. 
  
 Historically, the brain has been thought of as an immunologically privileged site, shielded 
behind the blood–brain barrier (BBB)4. However, recent evidence proposes that immune 
components of the brain, such as proinflammatory molecules, are able to cross the BBB and directly 
exert negative effects on neuronal cells, ultimately contributing to the development and 
progression of major depressive disorder (MDD), schizophrenia and post-traumatic stress disorder, 
amongst others 5,6. Cytokines such as IL-1β, IL-6, TNF-α, IFN-α and INF-y, as well as reactive oxygen 
species (ROS) and reactive nitrogen species (RNS), cause disruptions in neurogenesis, neuronal 
excitability, synaptic transmission, synaptic plasticity and neuronal survival 5-7, disturbances which 
have been implicated in the development and progression of neuropsychiatric disorders 8. 
Microglia, the resident innate immune cells of the CNS, are the major mediators of 
neuroinflammation 9, although monocytes and macrophages are also important innate immune 
sources of sources of proinflammatory molecules that can act in the CNS 10,11. These cells are 
strongly implicated in the pathogenesis of neuropsychiatric disorders therefore 12-14.  
 
 Over the past decades, the major difference between the adaptive and innate immune 
systems has been considered the ability of the adaptive immune system to retain memory for 
specific infectious agents, whilst the innate immune system has been considered neither capable of 
memory nor specificity 15. This memory function of the adaptive immune system is critical to 
immunity in vertebrates, often offering lifelong protection against reinfection. Recently however, 
cells of the innate immune system, including monocytes and macrophages, have been discovered 
capable of long-term functional memory following a single short lived immunostimulatory event, 
resulting in dramatically enhanced production of proinflammatory molecules in response to a 
subsequent, temporally distant, immunostimulatory event. This has been termed “trained innate 
immunity” or “innate immune memory” 16,17. In animal models of dysfunctional or absent adaptive 
immunity, trained innate immune cells can protect against lethal infection with various pathogens 
18,19. Trained innate immunity represents a paradigm shift therefore in our understanding of innate 
immunity, with important implications for disease pathogenesis and immunotherapeutics 16,20. 
 
 Trained innate immunity is distinct from priming. Priming is a well described phenomenon 
during certain infections or stimulations 16,20,21. Often, pre-exposure of an innate immune cell to a 
cytokine such as IFN-y is necessary for the cell to be able to fully activate and produce a robust 
immune response when exposed to a pathogen 22,23. The cells are said to be pre-activated or 
“primed” in response to stimulation with the cytokine. Typically, primed cells produce little, if any, 
cytokines in the absence of a contemporaneous co-stimulation by a pathogen 24,25. Priming effects 
also rapidly decline. In contrast, training is typically induced by pathogen associated molecular 
patterns (PAMPs), and involves long-term changes in innate immune cell function that persist well 
beyond the primary immunostimulatory event. Unlike primed cells, trained cells often have an 
elevated baseline proinflammatory cytokine production. The mechanisms underlying training are 
distinct from priming. Priming often involves the mobilization of pre-formed receptors in the 
cytoplasm to the plasma membrane as a result of a stimulus, leading to short-term term changes in 
receptor number or affinity 16,20. In contrast, training is underwritten by stable epigenetic changes 
in immune and metabolic pathways 16,20,21. This long term memory effect can persist for months, 
and possibly years, and is not exclusive or specific to the type of primary immune stimulating event 
26. Recent studies suggest that innate immune cells also retain long-term memory for non-infectious 
immunostimulatory challenges, such as stress 27. 
 
 Despite the widespread interest in immune function and psychiatric illness, there has been 
no exhaustive discussion relating to the implications of trained innate immunity on mental health 
pathology. Considering that trained innate immunity represents a paradigm shift in our 
understanding of immune function 8, the theoretical contributions of trained innate immunity to 
illnesses such as depression are potentially dramatic and worth of a comprehensive analysis. Here, 
we review recent evidence for innate immune training and examine why it is likely to be a major 
contributing factor to the pathogenesis of neuropsychiatric disorders. We concentrate primarily on 
monocytes, macrophages and microglia, though there is also extensive evidence for trained 
immunity in NK cells 16, which have themselves been recently hypothesized to play a role in 
psychiatric illness 28.  
 
 
Trained innate immunity 
 
The innate immune system and training 
 
 The innate immune system recognizes invading pathogens through receptors called 
pathogen recognition receptors (PRR), which are present on the surface, in the endosome or in the 
cytoplasm of innate immune cells 29. PRR recognize conserved microbial molecules including lipids, 
proteins, nucleic acids and carbohydrates. These microbial molecules are known as pathogen-
associated molecular patterns (PAMP) 29. A diverse range of PRR types exist, including toll-like 
receptors (TLR), C-type lectin receptors, nucleotide-binding oligomerization domain-like receptors 
(NOD), and retinoic acid-inducible gene I (RIG-I)-helicases 29. A specific PRR may be capable of 
recognizing a single or multiple different PAMP. TLR-4, for example, recognizes lipopolysaccharide 
(LPS), an endotoxin present in the cell wall of multiple different gram negative bacteria 30. Often, 
microorganisms will have multiple PAMP, which will together stimulate a suite of PRR on host cells. 
Herpes Simplex virus (HSV) PAMP activate TLR2 on the cell surface and TLR9 in the endosome 29 for 
example . 
 
 Typically, stimulation of a PRR by a PAMP leads to immune activation of the cell and the 
release of various proinflammatory cytokines, chemokines, ROS and RNS 29. The exact response may 
vary dependent on the type of PAMP-PRR interaction. However, many different PAMP-PRR 
interactions activate the same or similar downstream signaling pathways. Activation of a PRR by a 
PAMP can sometimes lead to an altered cellular immune response upon subsequent reactivation of 
the same PRR or the activation of a different PRR that feeds into similar signaling pathways. This has 
been known about for some time in the context of innate immune tolerance 31,32. Innate immune 
tolerance was first described in relation to the immunoparalysis that occurs after Gram-negative 
sepsis in critically ill patients 31. Here, cells of the innate immune system fail to mount an appropriate 
proinflammatory response to re-stimulation by LPS or Gram-negative bacteria following Gram-
negative sepsis. Thus, innate immune cells appear to retain an inhibitory memory for high dose LPS 
stimulation under certain conditions. Innate immune cells have also recently been shown to be 
capable of retaining a long-term memory for certain PAMP or pathogens, resulting in an 
exaggerated immune response upon subsequent re-stimulation with similar or dissimilar PAMP or 
pathogens. This heterogeneous proinflammatory memory effect, “trained innate immunity”, 
appears to be prolonged, lasting sometimes for months, and possibly even years 16. Whether 
tolerance or training occurs is dependent on a number of factors, including the amount, nature, 
duration of exposure of the PAMP. For example, whilst high dose LPS results in decreased 
production of proinflammatory molecules upon re-exposure to LPS, low dose LPS exposure results 
in increase production of proinflammatory molecules upon re-exposure to LPS 33. 
  
 That this memory effect is heterogeneous and long lasting has important implications, as it 
may set the stage for a proinflammatory responsive state in response to a diverse array of 
temporally distant immunostimulatory events. Table 1 lists some of the main features of trained 
innate immunity, as well as potential consequences for neuropsychiatric disorders. 
 
Training of monocytes and macrophages  
  
 Given that the adaptive immune system is highly specific, and the long held view that the 
innate immune system displays no memory for pathogens, we would not expect an enhanced 
immune response upon re-infection at a distant time with dissimilar organisms. Nor would we 
expect an enhanced immune response upon re-stimulation in the absence of a functional adaptive 
immune system. Several studies performed decades ago demonstrated just this though. Mice 
immunized with Bacillus Calmette–Guérin (BCG) displayed enhanced immunity and protection 
against lethal infection with non-tuberculous organisms such as Candida Albicans and Schistosoma 
Mansoni 18,34. T-lymphocyte depletion failed to dampen this protective effect, which was 
subsequently found to be mediated by activated tissue macrophages 18. Mice previously infected 
with the fungus Candida Albicans also showed enhanced immune responses and increased survival 
in response to infection with the Gram-positive bacterium Staphylococcus Aureus 35, an effect which 
was again found to be dependent on macrophage responses 19.  
 
 The importance of these findings and their implications were largely ignored however, until 
two recent studies replicated and extend these findings in human innate immune cells. 
Kleinnijenhuis et al (2012) isolated monocytes from adult humans before and two weeks after BCG 
vaccination, and stimulated them ex-vivo with BCG, Staphylococcus Aureus, Candida Albicans, or 
LPS 36. Post BCG vaccination, monocytes showed dramatically enhanced production (up to 7 fold) of 
various proinflammatory cytokines, including IFN-γ, TNF-α and IL-1β upon homogenous and 
heterogeneous stimulation, relative to monocytes pre BCG vaccination. This upregulation in 
proinflammatory function was accompanied by increased expression of various activation markers 
and PRRs, including CD11b, CD14, and TLR4, and was still present one year after BCG vaccination 26. 
Primary stimulation of NOD2, a PRR for mycobacteria, with the NOD2-specific ligand MDP, mimicked 
the training effects of BCG, which was prevented when inhibiting NOD2 during primary stimulation, 
as well as its downstream signaling pathway, Rip2 kinase. Such training effects were also seen in 
human monocytes following neonatal BCG vaccination 37.  
 
 Similar training effects were observed following stimulation of adult human monocytes in-
vitro with either Candida Albicans or β-glucan (a component of fungal cell walls) for 24 hours 38. 
Upon a second stimulation with Candida Albicans, bacteria, or various PAMP/PRR ligands up to two 
weeks later, pre-stimulated monocytes showed significant increases (of up to 10-fold) in TNF-α and 
IL-6 production relative to naive monocytes. The magnitude of the training effects was dependent 
on the doses of both the primary and secondary stimulation. Again, specifically inhibiting the PRR 
for β-glucan and its downstream signaling pathways during primary stimulation, in this case Dectin-
1 and Raf-1, prevented training. These training effects were accompanied by dramatic and long 
lasting changes in gene expression. Genes for multiple PRR unrelated to Candida/β-glucan were 
upregulated, including several TLRs, which might partly explain the heterogeneous effect of training. 
Other upregulated genes included chemokines and nitric oxide synthases, as well as several histone 
methyltransferases, suggesting a potential role for epigenetic remodeling in training.  
 
 For some PAMP, the dose can determine whether training or tolerance is induced, whereas 
for others, different doses appear to consistently induce training. For example, moderate to high 
doses of a variety of PAMP and PRR ligands, such as LPS (100 μg/ml), Pam3CSK4 (100 μg/ml), flagellin 
(10 μg/ml) and Poly(I:C) (100 μg/ml) (which all engage TLRs) induced heterogeneous tolerance in 
human monocytes 33. Lower doses (0.1 pg/ml to 1 μg/ml) however, induced heterogeneous training. 
In contrast, low to moderate doses of β-glucan (1 μg/ml), Tri-DAP (10 μg/ml) and MDP (10 μg/ml) 
(which engage NODs), all induced training (up to 5 fold increases in TNF-α). The reason why some 
PAMP/PRR induce only training or tolerance across a range of doses, whilst for other PAMP/PRR the 
effect is dose-dependent, is currently unclear.  
 Training of microglia 
 
 Few studies have investigated the long-term upregulation of microglial function as a result 
of a single immunostimulatory challenge, and none in the context of the concept of training. 
Nevertheless, there are suggestions that microglia are capable of being trained. Hippocampal 
microglia isolated from adult mice that had been injected once intra-peritonealy with Salmonella 
typhimurium and then given an intra-hippocampal injection of LPS four weeks later showed an 
increase in the activation markers CD11c and MHCII relative to microglia from mice only exposed to 
Salmonella typhimurium 39. Salmonella typhimurium injection alone did not result in an increase in 
CD11c and MHCII immunoreactivity, suggesting that the increase seen following LPS injection was 
not simply due to an increase in the number of microglia. Neonatal rats injected with Escherichia 
Coli subcutaneously and then given a peripheral injection of LPS in adulthood had increased 
microglial CD11b gene expression, as well as faster and more prolonged increases in microglial 
production of IL-1β protein, without there being any differences in microglial numbers 40,41. These 
changes were accompanied by decreased neurogenesis in the hippocampus and memory 
impairments, which were prevented when caspase-1 (a protease that cleaves the precursors pro-
IL-1β and pro-IL-18 into active IL-1β and IL-18) was inhibited prior to LPS challenge in adulthood. 
Although suggestive of training, it is possible, however, that interactions between the adaptive and 
the innate immune system were responsible for the observed effects in these studies. To specifically 
rule out interactions with other cell types, live microglia need to be isolated and tested in-vitro. 
Although animals with severe combined immunodeficiency could be used to rule out interactions 
with the adaptive immune system, this would still leave the possibility that other cell types such as 
astrocytes and neurons, which are known to have immunomodulatory properties 42,43, are 
responsible for any observed effects. A very limited number of studies have performed experiments 
on isolated microglia. Microglia isolated from adult rats that had been infected neonatally with 
Escherichia Coli showed increased production of IL-1β mRNA (on a per cell basis) when exposed to 
low dose LPS in-vitro 44. Again, neonatally infected rats had memory impairments when 
administered LPS in adulthood, which were prevented by administering minocycline prior to adult 
LPS challenge (which also prevented increases in IL-1β mRNA). Microglia isolated from the fetuses 
of maternal sheep injected with LPS and then maintained in-vitro for 3 weeks, had significantly 
higher production of IL-1β (> 4 fold) in response to LPS in-vitro relative to controls 45. The expression 
of heme oxygenase (decycling) 1 (HMOX1), which is thought to have an anti-inflammatory role 46, 
was strongly downregulated in LPS/LPS microglia.  
 
Training of innate immune cells by non-microbial stimuli 
 
 Upon cellular damage or stress, host cells release a variety of molecules. Some of these 
released molecules can activate PRR and initiate an inflammatory/immune response, much like 
PAMP. These endogenous PRR-stimulating non-microbial molecules are known as danger 
associated molecular patterns (DAMP) 47. Examples of DAMP include high mobility group box-1 
(HMGB1), S-100 proteins, heat-shock proteins (HSP), hyaluronan, surfactant protein, IFN-α, uric 
acid, fibronectin, beta defensin, and cardiolipin, amongst others 47. Many of these DAMP are 
oxidized versions of proteins and other molecules present on apoptotic host cells or in cellular debris 
48. These molecules are oxidized as a result of cellular damage/death induced ROS generation, 
resulting in hydrophobic regions being exposed and available to be recognized by PRR as DAMP 47. 
Many of these endogenous oxidized molecules and hydrophobic regions share molecular identity 
with microbial PAMP 47,48. Thus, we might expect DAMP to be also capable of inducing training. 
Exposure of human monocytes to oxidized low density lipoprotein (LDL) (1-10ug/ml) for 24 hours, 
but not LDL, for example results in increased protein production (up to 5 fold) of TNF-α, IL-6, IL-8, 
upon re-stimulation 7 days later with various TLR-4 (e.g. LPS) and TLR-2 agonists (e.g. Pam3Cys) 49. 
Blocking these TLR receptors or their downstream pathways inhibited the training effects.  
 
 The study above is the only study that we are aware that has directly investigated whether 
DAMP can induce training. There are, however, a few studies that provide indirect evidence for 
DAMP induced training. Sterile traumatic brain injury (TBI) releases a suite of DAMP 50, and might 
therefore be a systemic non-infectious immunostimulatory event capable of inducing microglial 
training. In humans, TBI is associated with microglial activation on PET decades later 51, and is a risk 
factor for depression 52. Microglia isolated from mice that had been injected peripherally with LPS 
one month after TBI showed increased IL-1β and TNF-α mRNA expression relative to microglia from 
LPS exposed only mice 53. This heightened microglial activity was accompanied by depressive-like 
behaviors in the mice. Although suggestive, this is not direct evidence for DAMP induced microglial 
training however, as TBI is a complex multifaceted phenomenon and the microglia were not 
stimulated ex-vivo, thus raising the possibility that interactions with other cell types may have been 
responsible for the upregulation of microglial proinflammatory function. Microglia isolated from 
mice 24 days after repeated social defeat stress (RSD) also had higher IL-1β, IL-6, and TNF-α mRNA 
expression and IL1-β protein production in response to ex-vivo LPS stimulation relative to non 
stressed controls 27. This upregulation in microglial proinflammatory function was accompanied by 
an increase in social avoidance behavior in RSD mice. Whether, specifically, stress induced released 
of DAMPs resulted in microglial training was not investigated however. Psychological and physical 
stress results in the release of a variety of DAMP both peripherally and centrally, including heat 
shock protein 72, uric acid and high mobility group box-1 54-56. Stressor exposure also releases 
microbial associated molecular patterns (MAMP) from the gut microbiota into the blood and/or 
extracellular environment 57. It seems likely that DAMP and MAMP, like PAMP, are capable of 
training innate immune cells. Given the strong association between stress, inflammation and 
neuropsychiatric illnesses, investigating whether stress induced release of DAMP or MAMP train 
microglia in a homogeneous and heterogeneous manner is an intriguing avenue of future study. 
 
Mechanisms underlying training 
 
 Several studies have specifically investigated whether training is underwritten by epigenetic 
remodeling. Human monocyte training as a result of BCG or Candida/β-glucan exposure results in 
an increase in H3K4me3, a histone modification associated with the regulation of immune-related 
genes, at the promoters of target genes including TNF-α, IL-6, IL-18 36,38. Consequently, blocking 
histone methylation by inhibition of histone methyltransferases prevented training. Training of 
monocytes by non-microbial stimuli, such as oxidized LDL, is also dependent on the enrichment of 
H3K4me3 at the promoters of various immune related genes 49. β-glucan training in human 
monocytes has also been associated with epigenetic remodeling of various metabolic pathways 58,59. 
β-glucan trained monocytes display reduced oxygen consumption and increased glucose 
consumption, consistent with a switch from oxidative metabolism to glycolysis. This metabolic shift 
is characteristic of activated monocytes and macrophages, and, as result, disrupting these changes 
in cellular metabolism inhibits training. Further, in mice, LPS induced macrophage training results in 
phosphorylation of the stress-response transcription factor ATF7 60. ATF7 normally suppresses a 
group of genes encoding factors involved in innate immunity in macrophages by recruiting the 
histone H3K9 dimethyltransferase G9a. Training leads to the release of ATF7 from chromatin and a 
decrease in repressive histone H3K9me2 marks, and thus increased expression of immune related 
genes. Interestingly, ATF7 is also phosphorylated as a result of social isolation stress and various 
other stressors 61.  
  Whilst to our knowledge there have been no studies investigating whether epigenetic 
remodeling is responsible for training effects in microglia, there is evidence that epigenetic 
remodeling does underlie tolerance in microglia. In response to a high dose in-vivo LPS exposure, 
isolated mouse microglia displayed reduced proinflammatory cytokine production upon a 
secondary LPS stimulation in-vitro 62. These effects were mediated by a reduction in the levels of 
H3K4me3 at the promoters of various immune related genes. Whilst proinflammatory cytokine 
production was diminished, phagocytic activity and nitric oxide production were enhanced 
however. This study is interesting, not only because it demonstrates that microglia are capable of 
functional epigenetic remodeling, but also because it shows that the dichotomy between innate 
immune tolerance versus training is potentially simplistic. Whilst some proinflammatory and 
neurotoxic innate immune cell functions may be downregulated, others may be simultaneously 
upregulated. Since proinflammatory cytokines, ROS and RNS all have the potential to be neurotoxic, 
it will be important to delineate the extent to which production of these different molecules are 
affected as a result of training. 
 
 
Implications for neuropsychiatric diseases 
 
 There remain a lot of unanswered questions regarding the details of trained innate 
immunity. We have listed some of these in Table 2. Most important, given the association between 
neuroinflammation and psychiatric disease, is whether trained innate immunity contributes to the 
onset and progression of neuropsychiatric disorders. A key unknown is also the duration for which 
training can last. That training in human monocytes has been detected up to a year post primary 
exposure suggests that training effects can be long-term. This is an important observation. Early-life 
immunostimulatory events such as stress and infection are risk factors for the development of 
neuropsychiatric disorders, and possibly neurodegenerative disorders, in adulthood 63.  Indeed, 
children prenatally exposed to elevated levels of the stress hormone cortisol reported persistent 
changes in the innate immunity with higher level of proinflammatory cytokines and subsequent 
development of emotional, behavioral and cognitive psychopathologies later in life 9-12. Similarly, 
mice prenatally exposed to a bacterial infection with LPS showed depression- and anxiety-related 
behaviors during adulthood. In addition, LPS-treated mice had reduced serotonin and noradrenaline 
levels in the hippocampus, a brain region very well-known for its neurogenenic properties 
associated with cognitive and memory functioning 13.  Therefore, evidence seems to suggest that 
specific long-term changes in the inflammatory environment is alone sufficient for the occurrence 
of several psychopathologies later in life. One way in which these events are thought to contribute 
to the development of neuropsychiatric illnesses is through the induction or a proinflammatory 
predisposed phenotype which can lead to neuroinflammation, in particular following a subsequent, 
temporally distant, immunostimulatory event. This ultimately results in the disruption of key 
processes involved in CNS development and regulation throughout adolescence and adulthood 63. 
These secondary immunostimulatory events can be completely unrelated in nature to the primary 
immunostimulatory event. In animal models for example, the combination of prenatal polyI:C 
(which activates TLR-3 64) followed by peripubertal stress 65, or TBI followed by LPS 53, induce 
depressive-like behaviours. These findings cannot be easily explained by adaptive immunity or 
classical understandings of innate immunity. That trained innate immunity is heterogeneous in 
nature, likely because different PAMP and DAMP can activate the same PRR or downstream 
signaling pathways, resulting in the reprogramming of similar epigenetic pathways, offers a 
potential mechanistic explanation. Adult microglia arise almost exclusively from a founding 
population of bone marrow-derived primitive macrophages during development and are 
maintained throughout life 66. Events early in life may lead to microglia later in life having a lower 
threshold for activation and/or the enhanced production of proinflammatory molecules that can 
cause impairments in neuroplasticity and neurogenesis.  
 
 Furthermore, after accounting for genetic factors, it is not clear why some individuals 
develop inflammation and psychiatric illness upon exposure to the same environmental risk factors 
whilst others do not 1. Trained innate immunity, specifically individual variation in the epigenetic 
landscape for immune-related genes and pathways as a result of previous inflammatory events, 
might account for some of the variation in how individuals respond to risk factors. It is possible that 
the presence of one inflammatory risk factor may train the innate immune system to react more 
vigorously in response to a subsequent, temporally distant, or even contemporaneous, 
inflammatory risk factor.  
 
 Once cells of the innate immune system such as microglia are trained, this could lead to a 
cycle in which (neuro)inflammation begets (neuro)inflammation (Figure 1). (Neuro)inflammation 
can  result in cell damage and death, and thus the release of numerous DAMP. As suggested, DAMP 
may themselves be capable of inducing training. Thus, as a result of infection or stress induced 
(neuro)inflammation and cell injury/death for example, the release of DAMP may train the innate 
immune system towards a proinflammatory phenotype, even if the initial (neuro)inflammatory 
insult did not. Upon secondary challenge at a distant time, the enhanced release of proinflammatory 
and neurotoxic molecules can then result in greater (neuro)inflammation, cell death, and DAMP 
release, and so on (Figure.1). This may explain, for example, how prior episodes of depression for 
example appear to sensitize immune responses to subsequent depressive episodes, with levels of 
proinflammatory cytokines and chemokines increasing with sequential depressive episodes 67,68. 
Indeed, several studies have found that baseline depression and/or anxiety, even subclinical, predict 
a later development of depression in hepatitis C Virus patients receiving the standard treatment 
with the proinflammatory cytokine IFN-α 14-17. One plausible hypothesis for such phenomenon is 
that upon primary challenge with the virus, DAMPs recognition by PRRs elicit antimicrobial 
responses that regulate facets of the innate immune system 8, which potentially predispose to the 
occurrence of a first episode of depression. In addition, such DAMPs-mediated training immunity 
implicates regulation of monocites to macrophages differentiation 8, which upon secondary 
challenge with IFN-α treatment may ultimately predispose the individual to a second episode of 
depression. Although several studies reported that a history of past psychiatric disturbance 
significantly increased the risk of depression during IFN-α therapy 18, on the other hand other studies 
did not find that a past history of depression significantly increases the risk of neuropsychiatric 
disturbance 14, 19-21. This suggests that having a blunted response is also plausible and that the 
release of DAMP in presence of (neuro)inflammation could theoretically result in tolerance. 
However, whether tolerance or training occurs may well be dependent on the nature, doses, 
duration and frequency of immunostimulatory events.  
 
 
Conclusion 
 
 Many questions relating to the contribution of trained innate immunity to disease onset and 
progression in neuropsychiatric disorders need to be addressed. The discovery of trained innate 
immunity has opened up a new dimension in the field of immunotherapeutics, such as vaccine 
development. It is likely that trained innate immunity will also have a significant impact on our 
understanding of disorders in which the innate immune system is implicated, including 
neuropsychiatric illnesses, as well as the development of novel treatments for such disorders. 
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Figure legend  
Figure 1. Trained innate immunity and a resulting neuroinflammatory cycle. Red represents an 
immune stimulation, blue represents a consequence. The release of DAMP is a consequence of 
neuronal injury and death, but can serve as a potential secondary immune stimulation, as well as a 
reinforcing stimulation for pre-existing training.  
 
